Companies / Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

Nasdaq: GLSICIK 1799788STAFFORD, TX

Financials

Revenue—
Net income$-19.36M
Total debt—
Cash$6.18M
Diluted EPS$-1.43
Shares outstanding14.7M

Ownership

14.7M shares outstanding · as of Jul 24, 2026
38.2%Insiders
Ownership
Insiders38.18%5,604,102
Institutions10.66%1,564,360
Public float51.16%7,509,746

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Patel SnehalCEOCEO and CFO · Director · 10% owner
38.18%5,604,102

Institutional holders 54

View all →
HolderValue% of shares
BlackRock, Inc.$11.40M3.31%
Vanguard Group Inc$6.23M2.02%
Geode Capital Management, LLC$3.74M1.06%
State Street Corporation$3.36M0.97%
Credit Agricole S a$1.83M0.59%
Northern Trust Corp$1.53M0.50%
Bank of New York Mellon Corp/The$1.12M0.32%
Marshall Wace, LLP$616.3K0.17%
Man Group plc$589.7K0.19%
Morgan Stanley$554.2K0.18%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Dec 31, 2025Patel Snehal
CEO
BuyCommon Stock$91.8K+4K
+0.08%
5,599,402
38.15% of shares
medium
Jan 12, 2026Patel Snehal
CEO
BuyCommon Stock$79.9K+3K
+0.05%
5,602,302
38.17% of shares
medium
Dec 30, 2025Patel Snehal
CEO
BuyCommon Stock$63.0K+3K
+0.05%
5,595,102
38.12% of shares
medium
Jan 13, 2026Patel Snehal
CEO
BuyCommon Stock$53.7K+2K
+0.03%
5,604,102
38.18% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
GLSICommon StockEquity396879108BBG00V6PT8C7